Key Takeaways SRPT reported a second fatality from acute liver failure after Elevidys gene therapy infusion. Sarepta suspends Elevidys dosing commercially and pauses the global ENVISION trial. Elevidys generated over half of the company's Q1 2025 revenue.Shares of Sarepta Therapeutics (SRPT) nosedived 42% in pre-market today after the company reported a second patient death following treatment with Elevidys, its one-shot gene therapy for Duchenne muscular dystrophy (DMD).This latest fatality was caused by ...